hsa-mir-196b: The identification of W-13, gefitinib, and exemestane in the present study was based on the eight GBM-associated genes (CDK6, RB1, CAMK2G, CAMK2B, NRAS, PRKCB, PDGFRA, and CALM3), which are targeted by the 10 DEMs (hsa-miR-196a, hsa-miR-10b, hsa-mir-196b, hsa-miR-18b, hsa-miR-542-3p, hsa-miR-219-2-3p, hsa-miR-1224-5p, hsa-miR-129-3p, hsa-miR-876-3p, and hsa-miR-770-5p) [1]. In a recent study on pancreatic ductal adenocarcinoma (PDAC) patients, it was found that those with hsa-mir-196b overexpression had worse survival outcomes [2]. This finding further supports the role of hsa-mir-196b as a potential biomarker for PDAC. References: [1] Zhang Y et al. Identification of key genes and miRNAs in glioblastoma-associated genes by bioinformatics analysis. World J Surg Oncol. 2019 Mar 6;17(1):47. doi: 10.1186/s12957-019-1599-y. [PMC6412522] [2] Zhang Y et al. Identification of key genes and miRNAs in pancreatic ductal adenocarcinoma by bioinformatics analysis. J Cell Biochem. 2019 Nov;120(11):19147-19157. doi: 10.1002/jcb.29011. [PMC6659773]